Why Did Bill Ackman Buy Alphabet Stock?
Bill Ackman has become famous in the investing world for…
Sell
32
AKTX Quote, Financials, Valuation and Earnings
Last price:
$1.48
Seasonality move
:
-0.24%
Day range:
$1.43 - $1.48
52-week range:
$0.85 - $4.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.86x
Volume:
2.5K
Avg. volume:
35.1K
1-year change:
20.17%
Market cap:
$41.3M
Revenue:
--
EPS (TTM):
-$2.75
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Akari Therapeutics PLC has 5494.41% upside to fair value with a price target of -- per share.
AKTX vs. S&P 500
-
Over the past 5 trading days, Akari Therapeutics PLC has overperformed the S&P 500 by 13.46% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Akari Therapeutics PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Akari Therapeutics PLC has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Akari Therapeutics PLC reported revenues of --.
Earnings Growth
-
Akari Therapeutics PLC has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Akari Therapeutics PLC reported earnings per share of -$0.24.
Enterprise value:
42M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.34x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -$16.8M | -$17.7M | -$5.1M | -$4.3M | |
| EBITDA | -- | -$15.6M | -$20M | -$4.1M | -$3.6M | |
| Diluted EPS | -- | $0.07 | -$2.01 | $1.16 | -$0.14 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $14.6M | $11.6M | -- | $4.3M | $3M | |
| Total Assets | $14.6M | $11.6M | -- | $4.4M | $50.6M | |
| Current Liabilities | $5.2M | $6.1M | -- | $4.6M | $19.9M | |
| Total Liabilities | $5.2M | $6.1M | -- | $4.6M | $28.3M | |
| Total Equity | $9.4M | $5.6M | -- | -$229K | $22.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$16.4M | -$12.6M | -$4.4M | -$2.1M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | $7M | $11M | $3.5M | $2.2M | |
| Free Cash Flow | -- | -$16.4M | -$12.6M | -$4.4M | -$2.1M | |
AKTX
Sector
Market Cap
$41.3M
$35M
Price % of 52-Week High
32.5%
44.47%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.9%
1-Year Price Total Return
20.17%
-38.53%
Beta (5-Year)
0.575
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.31
200-day SMA
Sell
Level
$2.08
Bollinger Bands (100)
Buy
Level
0.99 - 1.31
Chaikin Money Flow
Sell
Level
-1.9M
20-day SMA
Buy
Level
$1.21
Relative Strength Index (RSI14)
Buy
Level
62.11
ADX Line
Buy
Level
26.33
Williams %R
Neutral
Level
-26.3158
50-day SMA
Buy
Level
$1.13
MACD (12, 26)
Buy
Level
0.06
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
6.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
Stock Forecast FAQ
In the current month, AKTX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AKTX average analyst price target in the past 3 months is --.
-
Where Will Akari Therapeutics PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Akari Therapeutics PLC share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Akari Therapeutics PLC?
Analysts are divided on their view about Akari Therapeutics PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Akari Therapeutics PLC is a Sell and believe this share price will drop from its current level to --.
-
What Is Akari Therapeutics PLC's Price Target?
The price target for Akari Therapeutics PLC over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AKTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Akari Therapeutics PLC is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of AKTX?
You can purchase shares of Akari Therapeutics PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Akari Therapeutics PLC shares.
-
What Is The Akari Therapeutics PLC Share Price Today?
Akari Therapeutics PLC was last trading at $1.48 per share. This represents the most recent stock quote for Akari Therapeutics PLC. Yesterday, Akari Therapeutics PLC closed at $1.43 per share.
-
How To Buy Akari Therapeutics PLC Stock Online?
In order to purchase Akari Therapeutics PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Bill Ackman Buy Brookfield Stock?
Bill Ackman of Pershing Square Capital has made a number…
Why Is Chewy Stock Up — And Will It Keep Climbing?
We are all witnesses to the crazy e-commerce industry boom…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
27
SAIA alert for Apr 26
Saia [SAIA] is down 30.77% over the past day.
Sell
48
APPF alert for Apr 26
AppFolio [APPF] is down 18.16% over the past day.
Sell
15
KNSL alert for Apr 26
Kinsale Capital Group [KNSL] is down 16.33% over the past day.
